Lucie de Jonge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucie de Jonge has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Iris Lansdorp-Vogelaar
Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
8 shared publications- Iris Lansdorp-Vogelaar
Department of Public Health Erasmus University Medical Center Rotterdam The Netherlands
6 shared publications - Manon C. W. Spaander
Department of Gastroenterology and Hepatology Erasmus University Medical Center Rotterdam The Netherlands
5 shared publications - Esther Toes-Zoutendijk
Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands
4 shared publications - Emilie C. H. Breekveldt
Affiliations Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands, Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands
3 shared publications Esther Toes-Zoutendijk
Erasmus MC, Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by SAGE Publications in MDM Policy & Practice
- Vol. 11 (1)
Advancing the Evaluation of Risk-Stratified Colorectal Cancer Screening by Simulating Quantitative Fecal Hemoglobin Concentrations
Background. Growing evidence indicates that fecal hemoglobin (f-Hb) concentrations from prior negative fecal immunochemical tests (FITs) can predict the future detection of colorectal cancer (CRC) and advanced neoplasia. As a result, there are opportunities for risk-based screening tailored to prior FIT outcomes. However, current CRC screening decision models do not explicitly simulate quantitative f-Hb concentrations. They simulate only a binary positive or negative test result based on the sensitivity and specificity of the underlying lesions, which makes it impossible to evaluate risk-based screening by f-Hb with these models. Methods. We extended our well-established MISCAN-Colon microsimulation model with a module that simulates quantitative f-Hb concentrations based on age, sex, and the presence of colorectal lesions. This module was based on a zero-inflated negative binomial mixed-effect model and calibrated and validated using observational data from the Dutch national CRC screening program between 2014 and 2020. The new MISCAN-Colon was then applied to a case study, in which we compared the effectiveness of uniform biennial screening intervals versus risk-based intervals (3 y after a FIT result of 0 µg/g, 2 y after >0–15 µg/g, and 1 y after >15–46.9 µg/g). Results. The updated model closely reflected real-world results, including positivity rate (observed: 4.7%, model: 4.3%), CRC detection rates (observed: 0.3%, model: 0.4%), f-Hb distributions, and longitudinal patterns across 3 screening rounds. Compared with biennial screening, the risk-based strategy resulted in slightly more CRC cases (+5%) and deaths (+11%) but required substantially fewer FITs (−28%) and colonoscopies (−13%). Conclusions. Integrating the f-Hb module into MISCAN-Colon enables explicit modeling of f-Hb concentrations and facilitates the evaluation of risk-based screening by prior f-Hb concentrations. Highlights: In colorectal cancer screening (CRC), risk-based screening using fecal hemoglobin (f-Hb) from prior screening rounds has been suggested to improve the balance between the benefits and harms of screening. However, the added value of this approach has never been quantified because none of the existing decision models for CRC screening simulate f-Hb concentrations. We used data from the Dutch national CRC screening program to extend the widely used MISCAN-Colon microsimulation model to explicitly simulate an individual’s f-Hb concentration based on sex, age, and the presence of colorectal lesions. This model accurately reproduced cross-sectional and longitudinal associations between f-Hb concentration and screen-detected colorectal lesions, and model estimates showed that risk-based screening using f-Hb concentrations could be more efficient than current uniform screening.
- 1 January 2026
- Published by SAGE Publications in MDM Policy & Practice
- Vol. 11 (1)
Open AccessAdvancing the Evaluation of Risk-Stratified Colorectal Cancer Screening by Simulating Quantitative Fecal Hemoglobin Concentrations
Background. Growing evidence indicates that fecal hemoglobin (f-Hb) concentrations from prior negative fecal immunochemical tests (FITs) can predict the future detection of colorectal cancer (CRC) and advanced neoplasia. As a result, there are opportunities for risk-based screening tailored to prior FIT outcomes. However, current CRC screening decision models do not explicitly simulate quantitative f-Hb concentrations. They simulate only a binary positive or negative test result based on the sensitivity and specificity of the underlying lesions, which makes it impossible to evaluate risk-based screening by f-Hb with these models. Methods. We extended our well-established MISCAN-Colon microsimulation model with a module that simulates quantitative f-Hb concentrations based on age, sex, and the presence of colorectal lesions. This module was based on a zero-inflated negative binomial mixed-effect model and calibrated and validated using observational data from the Dutch national CRC screening program between 2014 and 2020. The new MISCAN-Colon was then applied to a case study, in which we compared the effectiveness of uniform biennial screening intervals versus risk-based intervals (3 y after a FIT result of 0 µg/g, 2 y after >0–15 µg/g, and 1 y after >15–46.9 µg/g). Results. The updated model closely reflected real-world results, including positivity rate (observed: 4.7%, model: 4.3%), CRC detection rates (observed: 0.3%, model: 0.4%), f-Hb distributions, and longitudinal patterns across 3 screening rounds. Compared with biennial screening, the risk-based strategy resulted in slightly more CRC cases (+5%) and deaths (+11%) but required substantially fewer FITs (−28%) and colonoscopies (−13%). Conclusions. Integrating the f-Hb module into MISCAN-Colon enables explicit modeling of f-Hb concentrations and facilitates the evaluation of risk-based screening by prior f-Hb concentrations. Highlights: In colorectal cancer screening (CRC), risk-based screening using fecal hemoglobin (f-Hb) from prior screening rounds has been suggested to improve the balance between the benefits and harms of screening. However, the added value of this approach has never been quantified because none of the existing decision models for CRC screening simulate f-Hb concentrations. We used data from the Dutch national CRC screening program to extend the widely used MISCAN-Colon microsimulation model to explicitly simulate an individual’s f-Hb concentration based on sex, age, and the presence of colorectal lesions. This model accurately reproduced cross-sectional and longitudinal associations between f-Hb concentration and screen-detected colorectal lesions, and model estimates showed that risk-based screening using f-Hb concentrations could be more efficient than current uniform screening.
- Open Access
- 5 September 2025
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 80, 102047
Global impact of COVID-19 on organized CRC screening programs: lessons learned
- 5 September 2025
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 80, 102047
Open AccessGlobal impact of COVID-19 on organized CRC screening programs: lessons learned
- Open Access
- 1 August 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (10) , 1095-1105
Cost-effectiveness of colon capsule endoscopy in colorectal cancer screening: a modeling study
The most used primary colorectal cancer (CRC) screening tests are the fecal immunochemical test (FIT) and colonoscopy. However, colonoscopy is an invasive procedure with possible (fatal) complications and FIT has shortcomings in test sensitivity. Colon capsule endoscopy (CCE) could be an alternative, but long-term effects are unknown. We assessed the cost-effectiveness of CCE in CRC screening.We simulated a Dutch cohort born between 1938 and 1957 for eight strategies: biennial FIT screening with cutoffs of 15 (FIT15) and 47 (FIT47) micrograms of hemoglobin per gram feces (µg Hb/g); biennial and triennial CCE screening; CCE after a FIT-negative result of 15–47 µg Hb/g (CCE triage); CCE after positive FIT using 15 and 47 µg Hb/g cutoffs; and 10-yearly colonoscopy screening. Three adherence scenarios were considered. We estimated lifetime CRC incidence, mortality, life years gained, and number of tests required. A cost-effectiveness analysis was performed to determine cost-effectiveness of each strategy.Triennial CCE and CCE triage screening had similar long-term outcomes to biennial FIT47. At 100% adherence, biennial CCE screening reduced CRC incidence from 79 to 49 cases (38.0% reduction) and mortality from 36 to 17 deaths (52.8% reduction) per 1000 individuals versus no screening. Life years gained increased to 155 per 1000 individuals versus 115 with biennial FIT47 (34.8% increase). However, these increases came at high financial cost, and CCE cost-effectiveness was dominated by biennial FIT and 10-yearly colonoscopy.CCE was not cost effective for CRC screening compared with biennial FIT and 10-yearly colonoscopy.
- 1 August 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (10) , 1095-1105
Open AccessCost-effectiveness of colon capsule endoscopy in colorectal cancer screening: a modeling study
The most used primary colorectal cancer (CRC) screening tests are the fecal immunochemical test (FIT) and colonoscopy. However, colonoscopy is an invasive procedure with possible (fatal) complications and FIT has shortcomings in test sensitivity. Colon capsule endoscopy (CCE) could be an alternative, but long-term effects are unknown. We assessed the cost-effectiveness of CCE in CRC screening.We simulated a Dutch cohort born between 1938 and 1957 for eight strategies: biennial FIT screening with cutoffs of 15 (FIT15) and 47 (FIT47) micrograms of hemoglobin per gram feces (µg Hb/g); biennial and triennial CCE screening; CCE after a FIT-negative result of 15–47 µg Hb/g (CCE triage); CCE after positive FIT using 15 and 47 µg Hb/g cutoffs; and 10-yearly colonoscopy screening. Three adherence scenarios were considered. We estimated lifetime CRC incidence, mortality, life years gained, and number of tests required. A cost-effectiveness analysis was performed to determine cost-effectiveness of each strategy.Triennial CCE and CCE triage screening had similar long-term outcomes to biennial FIT47. At 100% adherence, biennial CCE screening reduced CRC incidence from 79 to 49 cases (38.0% reduction) and mortality from 36 to 17 deaths (52.8% reduction) per 1000 individuals versus no screening. Life years gained increased to 155 per 1000 individuals versus 115 with biennial FIT47 (34.8% increase). However, these increases came at high financial cost, and CCE cost-effectiveness was dominated by biennial FIT and 10-yearly colonoscopy.CCE was not cost effective for CRC screening compared with biennial FIT and 10-yearly colonoscopy.
- Open Access
- 13 June 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 561, 119809
Modelling the impact of bias in fecal immunochemical testing on long-term outcomes of colorectal cancer screening
- 13 June 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 561, 119809
Open AccessModelling the impact of bias in fecal immunochemical testing on long-term outcomes of colorectal cancer screening
- Open Access
- 29 January 2024
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 75 (1) , 1-11
Effects on Cancer Prevention from the COVID-19 Pandemic
The COVID-19 pandemic led to disruption of health services around the world, including cancer services. We carried out a narrative review of the effect of the pandemic on cancer prevention services, including screening. Services were severely affected in the early months of the pandemic, and in some areas are still recovering. Large numbers of additional cancers or additional late-stage cancers have been predicted to arise over the coming years as a result of this disruption. To minimize the effects on cancer outcomes, it is necessary to return as quickly as possible to prepandemic levels of screening and prevention activity or indeed to exceed these levels. The recovery of services should address health inequalities.
- 29 January 2024
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 75 (1) , 1-11
Open AccessEffects on Cancer Prevention from the COVID-19 Pandemic
The COVID-19 pandemic led to disruption of health services around the world, including cancer services. We carried out a narrative review of the effect of the pandemic on cancer prevention services, including screening. Services were severely affected in the early months of the pandemic, and in some areas are still recovering. Large numbers of additional cancers or additional late-stage cancers have been predicted to arise over the coming years as a result of this disruption. To minimize the effects on cancer outcomes, it is necessary to return as quickly as possible to prepandemic levels of screening and prevention activity or indeed to exceed these levels. The recovery of services should address health inequalities.
- Open Access
- 15 June 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 190
Socio-demographic and cultural factors related to non-participation in the Dutch colorectal cancer screening programme
- 15 June 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 190
Open AccessSocio-demographic and cultural factors related to non-participation in the Dutch colorectal cancer screening programme
- Open Access
Impact of delayed screening invitations on screen-detected and interval cancers in the Dutch colorectal cancer screening programme: individual-level data analysis
Objective: To assess the impact of delayed invitation on screen-detected and interval colorectal cancers (CRC) within a faecal immunochemical testing (FIT)-based CRC screening programme.Design: All individuals that participated in 2017 and 2018 with a negative FIT and were eligible for CRC screening in 2019 and 2020 were included using individual-level data. Multivariable logistic regression analyses were used to assess the association between either the different time periods (ie, ‘before’, ‘during’ and ‘after’ the first COVID-19 wave) or the invitation interval on screen-detected and interval CRCs.Results: Positive predictive value for advanced neoplasia (AN) was slightly lowerduring(OR=0.91) andafter(OR=0.95) the first COVID-19 wave, but no significant difference was observed for the different invitation intervals. Out of all individuals that previously tested negative, 84 (0.004%) had an interval CRC beyond the 24 months since their last invitation. The time period of invitation as well as the extended invitation interval was not associated with detection rates for AN and interval CRC rate.Conclusion: The impact of the first COVID-19 wave on screening yield was modest. A very small proportion of the FIT negatives had an interval CRC possibly due to an extended interval, which potentially could have been prevented if they had received the invitation earlier. Nonetheless, no increase in interval CRC rate was observed, indicating that an extended invitation interval up to 30 months had no negative impact on the performance of the CRC screening programme and a modest extension of the invitation interval seems an appropriate intervention.
Open AccessImpact of delayed screening invitations on screen-detected and interval cancers in the Dutch colorectal cancer screening programme: individual-level data analysis
Objective: To assess the impact of delayed invitation on screen-detected and interval colorectal cancers (CRC) within a faecal immunochemical testing (FIT)-based CRC screening programme.Design: All individuals that participated in 2017 and 2018 with a negative FIT and were eligible for CRC screening in 2019 and 2020 were included using individual-level data. Multivariable logistic regression analyses were used to assess the association between either the different time periods (ie, ‘before’, ‘during’ and ‘after’ the first COVID-19 wave) or the invitation interval on screen-detected and interval CRCs.Results: Positive predictive value for advanced neoplasia (AN) was slightly lowerduring(OR=0.91) andafter(OR=0.95) the first COVID-19 wave, but no significant difference was observed for the different invitation intervals. Out of all individuals that previously tested negative, 84 (0.004%) had an interval CRC beyond the 24 months since their last invitation. The time period of invitation as well as the extended invitation interval was not associated with detection rates for AN and interval CRC rate.Conclusion: The impact of the first COVID-19 wave on screening yield was modest. A very small proportion of the FIT negatives had an interval CRC possibly due to an extended interval, which potentially could have been prevented if they had received the invitation earlier. Nonetheless, no increase in interval CRC rate was observed, indicating that an extended invitation interval up to 30 months had no negative impact on the performance of the CRC screening programme and a modest extension of the invitation interval seems an appropriate intervention.
- Open Access
- 15 March 2023
- Published by Elsevier in Preventive Medicine
- Vol. 170, 107488
Risk prediction for advanced neoplasia using longitudinal adherence measures to fecal immunochemical test-based colorectal cancer screening programs
- 15 March 2023
- Published by Elsevier in Preventive Medicine
- Vol. 170, 107488
Open AccessRisk prediction for advanced neoplasia using longitudinal adherence measures to fecal immunochemical test-based colorectal cancer screening programs
- Open Access
- 1 December 2022
- Published by Wiley in International Journal of Cancer
- Vol. 152 (8) , 1536-1546
Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT‐based CRC screening program
The interval colorectal cancer (CRC) rate after negative fecal immunochemical testing (FIT) is an important quality indicator of CRC screening programs. We analyzed the outcomes of two rounds of the FIT‐based CRC screening program in the Netherlands, using data from individuals who participated in FIT‐screening from 2014 to 2017. Data of individuals with one prior negative FIT (first round) or two prior negative FITs (first and second round) were included. Outcomes included the incidence of interval CRC in FIT‐negative participants (40‐46.9 μg/g) had a higher probability of detecting an interval CRC (OR 16.9; 95%CI: 14.0‐20.4) than had participants with unmeasurable f‐Hb (0‐2.6 μg/g). After two screening rounds, the odds ratio for interval CRC was 12.0 (95%CI: 7.8‐17.6) for participants with f‐Hb just below the cut‐off compared with participants with unmeasurable f‐Hb. After both screening rounds, the Dutch CRC screening program had a low incidence of interval CRC and an associated high FIT‐sensitivity. Our findings suggest there is a potential for further optimizing CRC screening programs with the use of risk‐stratified CRC screening based on prior f‐Hb.
- 1 December 2022
- Published by Wiley in International Journal of Cancer
- Vol. 152 (8) , 1536-1546
Open AccessFactors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT‐based CRC screening program
The interval colorectal cancer (CRC) rate after negative fecal immunochemical testing (FIT) is an important quality indicator of CRC screening programs. We analyzed the outcomes of two rounds of the FIT‐based CRC screening program in the Netherlands, using data from individuals who participated in FIT‐screening from 2014 to 2017. Data of individuals with one prior negative FIT (first round) or two prior negative FITs (first and second round) were included. Outcomes included the incidence of interval CRC in FIT‐negative participants (40‐46.9 μg/g) had a higher probability of detecting an interval CRC (OR 16.9; 95%CI: 14.0‐20.4) than had participants with unmeasurable f‐Hb (0‐2.6 μg/g). After two screening rounds, the odds ratio for interval CRC was 12.0 (95%CI: 7.8‐17.6) for participants with f‐Hb just below the cut‐off compared with participants with unmeasurable f‐Hb. After both screening rounds, the Dutch CRC screening program had a low incidence of interval CRC and an associated high FIT‐sensitivity. Our findings suggest there is a potential for further optimizing CRC screening programs with the use of risk‐stratified CRC screening based on prior f‐Hb.
- Open Access
- 24 June 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (6) , e0270223
Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic
Objective: The COVID-19 pandemic forced colorectal cancer (CRC) screening programs to downscale their colonoscopy capacity. In this study, we assessed strategies to deal with temporary restricted colonoscopy capacity in a FIT-based CRC screening program while aiming to retain the maximum possible preventive effect of the screening program. Design: We simulated the Dutch national CRC screening program inviting individuals between ages 55 and 75 for biennial FIT using the MISCAN-Colon model including the 3-month disruption in the first half of 2020 due to the COVID-19 pandemic. For the second half of 2020 and 2021, we simulated three different strategies for the total target population: 1) increasing the FIT cut-off, 2) skipping one screening for specific screening ages, and 3) extending the screening interval. We estimated the impact on required colonoscopy capacity in 2020–2021 and life years (LYs) lost in the long-term. Results: Increasing the FIT cut-off, skipping screening ages and extending the screening interval resulted in a maximum reduction of 25,100 (-17.0%), 16,100(-10.9%) and 19,000 (-12.9%) colonoscopies, respectively. Modelling an increased FIT cut-off, the number of LYs lost ranged between 1,400 and 4,400. Skipping just a single screening age resulted in approximately 2,700 LYs lost and this was doubled in case of skipping two screening ages. Extending the screening interval up to 34 months had the smallest impact on LYs lost (up to 1,100 LYs lost). Conclusion: This modelling study shows that to anticipate on restricted colonoscopy capacity, temporarily extending the screening interval retains the maximum possible preventive effect of the CRC screening program.
- 24 June 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (6) , e0270223
Open AccessModelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic
Objective: The COVID-19 pandemic forced colorectal cancer (CRC) screening programs to downscale their colonoscopy capacity. In this study, we assessed strategies to deal with temporary restricted colonoscopy capacity in a FIT-based CRC screening program while aiming to retain the maximum possible preventive effect of the screening program. Design: We simulated the Dutch national CRC screening program inviting individuals between ages 55 and 75 for biennial FIT using the MISCAN-Colon model including the 3-month disruption in the first half of 2020 due to the COVID-19 pandemic. For the second half of 2020 and 2021, we simulated three different strategies for the total target population: 1) increasing the FIT cut-off, 2) skipping one screening for specific screening ages, and 3) extending the screening interval. We estimated the impact on required colonoscopy capacity in 2020–2021 and life years (LYs) lost in the long-term. Results: Increasing the FIT cut-off, skipping screening ages and extending the screening interval resulted in a maximum reduction of 25,100 (-17.0%), 16,100(-10.9%) and 19,000 (-12.9%) colonoscopies, respectively. Modelling an increased FIT cut-off, the number of LYs lost ranged between 1,400 and 4,400. Skipping just a single screening age resulted in approximately 2,700 LYs lost and this was doubled in case of skipping two screening ages. Extending the screening interval up to 34 months had the smallest impact on LYs lost (up to 1,100 LYs lost). Conclusion: This modelling study shows that to anticipate on restricted colonoscopy capacity, temporarily extending the screening interval retains the maximum possible preventive effect of the CRC screening program.